Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Revisão |
| Jezik: | engleski |
| Izdano: |
2014
|
| Online pristup: | https://doi.org/10.1517/14728222.2014.960843 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|